George Coukos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
George Coukos has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Lana Elias Kandalaft
Swiss Medical Network, Clinique de Genolier, Genolier, Switzerland; Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland; Department of Oncology, University of Lausanne, Lausanne, Switzerland
52 shared publications - Denarda Dangaj Laniti
Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland
29 shared publications Lin Zhang
Ovarian Cancer Research Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA
28 shared publications- Alexandre Harari
Department of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland
26 shared publications - Michal Bassani-Sternberg
University Hospital of Lausanne, Lausanne, Switzerland
25 shared publications - Nicola Vannini
University of Fribourg (UNIFR), Fribourg, Switzerland
24 shared publications
Latest Publications
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Combinatorial Delivery of Low-Dose Radiotherapy and Immunotherapy to Patients with Immune-Excluded Tumors Enhances CD8+ T-cell Functionality
Supplementary Table 6 from Combinatorial Delivery of Low-Dose Radiotherapy and Immunotherapy to Patients with Immune-Excluded Tumors Enhances CD8+ T-cell Functionality
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Combinatorial Delivery of Low-Dose Radiotherapy and Immunotherapy to Patients with Immune-Excluded Tumors Enhances CD8+ T-cell Functionality
Supplementary Table 6 from Combinatorial Delivery of Low-Dose Radiotherapy and Immunotherapy to Patients with Immune-Excluded Tumors Enhances CD8+ T-cell Functionality
- Open Access
- 4 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (14) , OF1-OF20
Combinatorial Delivery of Low-Dose Radiotherapy and Immunotherapy to Patients with Immune-Excluded Tumors Enhances CD8+ T-cell Functionality
Purpose: Immune-checkpoint blockade (ICB) has demonstrated efficacy across tumor types. However, “cold” tumors characterized by low intraepithelial T-cell infiltration exhibit poor responsiveness. We investigated whether low-dose radiotherapy (LDRT) could enhance ICB efficacy in patients with multimetastatic immune-excluded solid tumors. Patients and Methods: We conducted a multicohort phase I clinical trial (RACIN) involving 25 patients treated with escalating doses of LDRT in combination with a backbone regimen of nivolumab, ipilimumab, aspirin, or celecoxib and low-dose cyclophosphamide. The primary endpoints were safety and tolerability; secondary endpoints included disease control rate (DCR), progression-free survival, and overall survival. Exploratory endpoint analyses used paired pre- and post-LDRT tumor biopsies for single-cell profiling of the tumor microenvironment (TME). Results: The combination therapy showed a manageable safety profile, with grade ≥3 adverse events in 12% to 21% of patients. The overall DCR was 42%, with one patient with ovarian cancer maintaining a complete response at 3 years. In responders, enhanced CD8+ tumor-infiltrating lymphocyte (TIL) functionality was associated with increased DNA damage response signatures and the presence of PD-1+CD8+ TILs at baseline. In contrast, nonresponders exhibited heightened immune regulatory innate lymphocytes such as CD8 Mucosal-Associated Invariant T (MAIT) and regulatory natural killer (NK) cells at baseline, accompanied by a lack of immunostimulatory myeloid cells in the TME and increased TIL radiosensitivity after LDRT. Conclusions: These findings suggest that LDRT combined with ICB is safe and may contribute to immunomodulatory activity in immune-excluded tumors. CD8+ TIL dynamics, DNA repair responsiveness, and TME composition may predict response and merit further validation in controlled larger studies.
- 4 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (14) , OF1-OF20
Open AccessCombinatorial Delivery of Low-Dose Radiotherapy and Immunotherapy to Patients with Immune-Excluded Tumors Enhances CD8+ T-cell Functionality
Purpose: Immune-checkpoint blockade (ICB) has demonstrated efficacy across tumor types. However, “cold” tumors characterized by low intraepithelial T-cell infiltration exhibit poor responsiveness. We investigated whether low-dose radiotherapy (LDRT) could enhance ICB efficacy in patients with multimetastatic immune-excluded solid tumors. Patients and Methods: We conducted a multicohort phase I clinical trial (RACIN) involving 25 patients treated with escalating doses of LDRT in combination with a backbone regimen of nivolumab, ipilimumab, aspirin, or celecoxib and low-dose cyclophosphamide. The primary endpoints were safety and tolerability; secondary endpoints included disease control rate (DCR), progression-free survival, and overall survival. Exploratory endpoint analyses used paired pre- and post-LDRT tumor biopsies for single-cell profiling of the tumor microenvironment (TME). Results: The combination therapy showed a manageable safety profile, with grade ≥3 adverse events in 12% to 21% of patients. The overall DCR was 42%, with one patient with ovarian cancer maintaining a complete response at 3 years. In responders, enhanced CD8+ tumor-infiltrating lymphocyte (TIL) functionality was associated with increased DNA damage response signatures and the presence of PD-1+CD8+ TILs at baseline. In contrast, nonresponders exhibited heightened immune regulatory innate lymphocytes such as CD8 Mucosal-Associated Invariant T (MAIT) and regulatory natural killer (NK) cells at baseline, accompanied by a lack of immunostimulatory myeloid cells in the TME and increased TIL radiosensitivity after LDRT. Conclusions: These findings suggest that LDRT combined with ICB is safe and may contribute to immunomodulatory activity in immune-excluded tumors. CD8+ TIL dynamics, DNA repair responsiveness, and TME composition may predict response and merit further validation in controlled larger studies.